supp.fit

Berberine: study protocols

70 study groups say how much Berberine participants took a day. These are the doses the studies gave. They are not a recommendation.

Berberine: what the research found →

Dose per serving from products

258 products in our catalogue print how much Berberine a serving holds.

Most common: 250 mg to 500 mg, 25% of 258 products.

Dose per servingProducts
2.5 mg to 5 mg
23
5 mg to 10 mg
13
10 mg to 25 mg
15
25 mg to 50 mg
28
50 mg to 100 mg
19
100 mg to 250 mg
54
250 mg to 500 mg
65
500 mg to 1 g
19
1 g to 2.5 g
21
over 2.5 g
1

Dose per serving from research

70 study groups in 52 studies say how much Berberine participants took a day.

These are the doses the studies gave. They are not a recommendation.

Most common: 500 mg to 1 g, 53% of 70 study groups.

Daily doseStudy groups
250 mg or less
4
250 mg to 500 mg
12
500 mg to 1 g
37
1 g to 2.5 g
17

Commonly used together

18 of 70 study groups took Berberine with something else. Shown: what 3 or more different studies gave.

What was given together, not what works together.

Taken withStudy groups
Red Yeast Rice
11
Policosanol
9
Coenzyme Q10
6
Folic Acid
5
Astaxanthin
4

70 study groups

Study
Berberine versus placebo for the prevention of recurrence of colorectal adenoma: a multicentre, double-blinded, randomised controlled study
2020 · berberine group · Adults aged 18–75 with one to six histologically confirmed colorectal adenomas removed by polypectomy
600 mg2 years553
A randomized, multicenter and noninferiority study of amoxicillin plus berberine vs tetracycline plus furazolidone in quadruple therapy for Helicobacter pylori rescue treatment
2020 · berberine and amoxycillin (BA)-based quadruple therapy group · Adults aged 18–70 years, either sex, with H. pylori infection whose eradication treatment had previously failed at least once
900 mg2 weeks329
Efficacy and safety of triple therapy containing berberine hydrochloride, amoxicillin, and rabeprazole in the eradication of Helicobacter pylori
2022 · berberine triple scheme (observation group) · Adults aged 18–70 with initial Helicobacter pylori infection and dyspepsia, who had not previously received eradication therapy
900 mg2 weeks262
Efficacy and safety of triple therapy containing berberine, amoxicillin, and vonoprazan for Helicobacter pylori initial treatment: A randomized controlled trial
2023 · A group (berberine triple therapy) · Adults aged 18–70 years, both sexes, with untreated initial Helicobacter pylori infection and dyspepsia symptoms
1 g2 weeks100
Effect of berberine administration on metabolic syndrome, insulin sensitivity, and insulin secretion
2013 · Berberine group · Patients with metabolic syndrome; age and sex distribution not reported
1.5 g90 days12
Adjunctive berberine reduces antipsychotic-associated weight gain and metabolic syndrome in patients with schizophrenia: a randomized controlled trial
2022 · berberine · People with schizophrenia spectrum disorders and antipsychotic-associated weight gain who had developed metabolic syndrome
600 mg12 weeks58
Improvement of adjunctive berberine treatment on negative symptoms in patients with schizophrenia
2022 · berberine group · Patients with schizophrenia receiving adjunctive atypical antipsychotic treatment
900 mg8 weeks32
Berberine treatment for weight gain in patients with schizophrenia by regulating leptin rather than adiponectin
2022 · berberine group · Patients with schizophrenia on a stable dose of a single antipsychotic for at least one month
900 mg8 weeks27
Berberine inhibits acute radiation intestinal syndrome in human with abdomen radiotherapy
2010 · Berberine trial group · Patients with cervical cancer receiving pelvic radiotherapy; age and sex not reported
900 mg—21
Berberine inhibits acute radiation intestinal syndrome in human with abdomen radiotherapy
2010 · Berberine oral group · Patients with seminoma or lymphoma receiving abdominal radiotherapy; age and sex not reported
900 mg—18
Berberine inhibits acute radiation intestinal syndrome in human with abdomen radiotherapy
2010 · Berberine treatment for patients with radiation-induced acute intestinal symptoms · Patients with radiation-induced acute intestinal symptoms receiving abdominal or pelvic radiotherapy; age and sex not reported
900 mg3 weeks8
Berberine containing quadruple therapy for initial Helicobacter pylori eradication: An open-label randomized phase IV trial
2017 · berberine-containing quadruple therapy · Adults aged 18–70 with documented Helicobacter pylori infection and upper gastrointestinal symptoms
200 mg2 weeks304
A Randomized Clinical Trial of Berberine Hydrochloride in Patients with Diarrhea-Predominant Irritable Bowel Syndrome
2015 · berberine group · Patients with diarrhea-predominant irritable bowel syndrome (IBS-D); age and sex not reported
400 mg8 weeks—
Berberine Ursodeoxycholate for the Treatment of Type 2 Diabetes: A Randomized Clinical Trial
2025 · 500-mg group · Adults aged 41-76 with type 2 diabetes
1 g12 weeks37
Efficacy of berberine in patients with type 2 diabetes mellitus
2008 · Berberine group, study B (combination therapy) · Adults with type 2 diabetes inadequately controlled on diet and existing antidiabetic therapy
1.5 g13 weeks48
Berberine Ursodeoxycholate for the Treatment of Type 2 Diabetes: A Randomized Clinical Trial
2025 · 1000-mg group · Adults aged 41-76 with type 2 diabetes
2 g12 weeks38
Optimizing Lipid Pattern by Adding a Combined Nutraceutical or Pravastatin to Fenofibrate Treatment in Hypertriglyceridemic Subjects: Single Site, Randomized, Open-Label, Post-Market Clinical Investigation
2018 · combined lipid-lowering nutraceutical (Armolipid Plus®) · Adults with hypertriglyceridemia and residual dyslipidemia, already tolerating micronized fenofibrate; ages and sex not reported
500 mg8 weeks20
Efficacy of berberine in patients with type 2 diabetes mellitus
2008 · Berberine group, study A (monotherapy) · Adults aged 25–75 with newly diagnosed type 2 diabetes
1.5 g13 weeks18
Emulsification by vitamin E TPGS or Quillaja extract enhanced absorption of berberine without affecting its metabolism in humans
2022 · Berberine powder · Healthy men and women
800 mg1 day12
Berberine ameliorates inflammation in patients with acute coronary syndrome following percutaneous coronary intervention
2012 · berberine-treated group · Adults with acute coronary syndrome undergoing percutaneous coronary intervention; age and sex not specified
900 mg30 days61
[Effects of berberine on serum inflammatory factors and carotid atherosclerotic plaques in patients with acute cerebral ischemic stroke]
2016 · berberine group · Patients with acute cerebral ischemic stroke
900 mg90 days60
Effects of berberine on the blood concentration of cyclosporin A in renal transplanted recipients: clinical and pharmacokinetic study
2005 · BBR-treated group · Renal-transplant recipients receiving cyclosporin A
600 mg90 days52
[Therapeutic Effects of Berberine Capsule on Patients with Mild Hyperlipidemia]
2016 · berberine group (the treatment group) · Patients with mild hyperlipidemia; ages and sex not reported
900 mg26 weeks49
Effectiveness and safety of Bifidobacterium and berberine in human hyperglycemia and their regulatory effect on the gut microbiota: a multi-center, double-blind, randomized, parallel-controlled study
2021 · Be group (berberine) · Adults aged 18–70 with newly diagnosed hyperglycemia
1 g16 weeks49
Effect of Berberine on Cardiovascular Disease Risk Factors: A Mechanistic Randomized Controlled Trial
2021 · berberine group · Chinese men aged 20–65 with hyperlipidemia and no history of chronic diseases
1 g12 weeks42
Effect of Berberine Hydrochloride on the Diversity of Intestinal Flora in Parkinson's Disease Patients
2022 · observation group · Patients with Parkinson's disease; age and sex not specified
600 mg90 days34
Berberine alleviates oxidized low-density lipoprotein-induced macrophage activation by downregulating galectin-3 via the NF-κB and AMPK signaling pathways
2019 · BBR group · Adults with acute coronary syndrome who had undergone primary or elective PCI; mean age 64.7 years in this arm
900 mg90 days30
Repeated administration of berberine inhibits cytochromes P450 in humans
2012 · berberine capsules · Healthy Chinese male volunteers, mean age 21.6 years; no stated condition
900 mg2 weeks18
Berberine is an insulin secretagogue targeting the KCNH6 potassium channel
2021 · BBR treatment · Healthy men aged 18–45 years with normal glucose tolerance
1 g1 day15
A Randomized, Dose-Finding, Proof-of-Concept Study of Berberine Ursodeoxycholate in Patients With Primary Sclerosing Cholangitis
2022 · HTD1801 500 mg BID · Patients with primary sclerosing cholangitis
1 g6 weeks15
Inflammatory markers and noncoding-RNAs responses to low and high compressions of HIIT with or without berberine supplementation in middle-aged men with prediabetes
2024 · HC + BBR · Middle-aged men with overweight or obesity and prediabetes
1 g8 weeks9
Inflammatory markers and noncoding-RNAs responses to low and high compressions of HIIT with or without berberine supplementation in middle-aged men with prediabetes
2024 · LC + BBR · Middle-aged men with overweight or obesity and prediabetes
1 g8 weeks9
Inflammatory markers and noncoding-RNAs responses to low and high compressions of HIIT with or without berberine supplementation in middle-aged men with prediabetes
2024 · BBR · Middle-aged men with overweight or obesity and prediabetes
1 g8 weeks9
Effects of berberine on the blood concentration of cyclosporin A in renal transplanted recipients: clinical and pharmacokinetic study
2005 · Pharmacokinetic study BBR co-administration phase · Six renal-transplant recipients receiving cyclosporin A
600 mg12 days6
Treatment of type 2 diabetes and dyslipidemia with the natural plant alkaloid berberine
2008 · berberine group · Patients with type 2 diabetes and dyslipidemia
1 g90 days—
Effects of berberine on lipid profile in subjects with low cardiovascular risk
2013 · berberine · Caucasian subjects with low cardiovascular risk
1 g26 weeks—
Pharmacokinetic interactions and tolerability of berberine chloride with simvastatin and fenofibrate: an open-label, randomized, parallel study in healthy Chinese subjects
2019 · Bbr 300 mg · Healthy Chinese men and women aged 18–50 years
900 mg7 days—
Pharmacokinetic interactions and tolerability of berberine chloride with simvastatin and fenofibrate: an open-label, randomized, parallel study in healthy Chinese subjects
2019 · Bbr 300 mg plus Svt 40 mg · Healthy Chinese men and women aged 18–50 years
900 mg7 days—
Pharmacokinetic interactions and tolerability of berberine chloride with simvastatin and fenofibrate: an open-label, randomized, parallel study in healthy Chinese subjects
2019 · Bbr 300 mg plus Fbt 200 mg · Healthy Chinese men and women aged 18–50 years
900 mg7 days—
The effect of berberine adjunctive treatment on glycolipid metabolism in patients with schizophrenia: A randomized, double-blind, placebo-controlled clinical trial
2021 · berberine · Patients diagnosed with schizophrenia
900 mg8 weeks—
Nutraceutical pill containing berberine versus ezetimibe on plasma lipid pattern in hypercholesterolemic subjects and its additive effect in patients with familial hypercholesterolemia on stable cholesterol-lowering treatment
2012 · BBR/P/RR monotherapy · Adults with primary polygenic hypercholesterolemia who were statin-intolerant or declined statin treatment
500 mg180 days152
Nutraceutical pill containing berberine versus ezetimibe on plasma lipid pattern in hypercholesterolemic subjects and its additive effect in patients with familial hypercholesterolemia on stable cholesterol-lowering treatment
2012 · Supplementary BBR/P/RR in HeFH patients on stable statin treatment or statin plus ezetimibe · Adults with genotype-confirmed heterozygous familial hypercholesterolemia on stable-dose statins or statins plus ezetimibe
500 mg90 days30
Nutraceutical pill containing berberine versus ezetimibe on plasma lipid pattern in hypercholesterolemic subjects and its additive effect in patients with familial hypercholesterolemia on stable cholesterol-lowering treatment
2012 · Combined BBR/P/RR plus ezetimibe therapy · Adults with primary hypercholesterolemia selected for a low response to monotherapy
500 mg90 days26
Effects of a new combination of nutraceuticals with Morus alba on lipid profile, insulin sensitivity and endotelial function in dyslipidemic subjects. A cross-over, randomized, double-blind trial
2015 · Combination B · Adults aged 18–70 with hypercholesterolemia not requiring statins or statin-intolerant
531 mg4 weeks23
Emulsification by vitamin E TPGS or Quillaja extract enhanced absorption of berberine without affecting its metabolism in humans
2022 · Quillaja extract-emulsified berberine · Healthy men and women
800 mg1 day12
Absorption Kinetics of Berberine and Dihydroberberine and Their Impact on Glycemia: A Randomized, Controlled, Crossover Pilot Trial
2021 · B500 (berberine) · Healthy, physically active males aged 18–45 years; five participants completed the study.
1.5 g2 days5
Effects of a new combination of nutraceuticals with Morus alba on lipid profile, insulin sensitivity and endotelial function in dyslipidemic subjects. A cross-over, randomized, double-blind trial
2015 · Combination A · Adults aged 18–70 with hypercholesterolemia not requiring statins or statin-intolerant
500 mg4 weeks23
Effect of a food supplement containing berberine, monacolin K, hydroxytyrosol and coenzyme Q(10) on lipid levels: a randomized, double-blind, placebo controlled study
2017 · Body Lipid (BL) · Adults aged 18–75, both sexes, with mild-to-moderate hypercholesterolemia
500 mg4 weeks—
Effect of a food supplement containing berberine, monacolin K, hydroxytyrosol and coenzyme Q(10) on lipid levels: a randomized, double-blind, placebo controlled study
2017 · Armolipid Plus (AM) · Adults aged 18–75, both sexes, with mild-to-moderate hypercholesterolemia
500 mg4 weeks—
Efficacy of Berberine in Patients with Non-Alcoholic Fatty Liver Disease
2015 · Group C — LSI plus BBR · Adults with NAFLD and impaired glucose regulation or type 2 diabetes of less than 1 year’s duration
1.5 g16 weeks62
[Effects of berberine on the serum cystatin C levels and urine albumin/creatine ratio in patients with type 2 diabetes mellitus]
2018 · intervention group · Adults aged approximately 55 years with type 2 diabetes mellitus
1.2 g26 weeks57
Lipid profiling of the therapeutic effects of berberine in patients with nonalcoholic fatty liver disease
2016 · Group B—LSI plus BBR · Adults with NAFLD and impaired glucose regulation or type 2 diabetes
1.5 g16 weeks41
Does berberine impact anthropometric, hepatic, and metabolic parameters in patients with metabolic dysfunction-associated fatty liver disease? Randomized, double-blind placebo-controlled trial
2024 · BBR group · Adults with metabolic dysfunction-associated fatty liver disease (MAFLD); age range and sex not specified
1.5 g12 weeks35
The Influence of Berberine on Vascular Function Parameters, Among Them VEGF, in Individuals with MAFLD: A Double-Blind, Randomized, Placebo-Controlled Trial
2025 · Group 1 (berberine group) · Adults aged 40–60 years with MAFLD, BMI 27.0–34.9 kg/m², and abdominal obesity; women were at least one year post-menopause.
1.5 g12 weeks35
Comparative Effects of Gymnema sylvestre and Berberine on Adipokines, Body Composition, and Metabolic Parameters in Obese Patients: A Randomized Study
2024 · Group B (BBR) · Mexican adults over 18 years of both genders with obesity (BMI >30 kg/m²), no previous T2DM diagnosis, and at least two T2DM risk factors
1.5 g90 days25
A Randomized, Dose-Finding, Proof-of-Concept Study of Berberine Ursodeoxycholate in Patients With Primary Sclerosing Cholangitis
2022 · HTD1801 1000 mg BID · Patients with primary sclerosing cholangitis
2 g6 weeks24
Berberine phospholipid exerts a positive effect on the glycemic profile of overweight subjects with impaired fasting blood glucose (IFG): a randomized double-blind placebo-controlled clinical trial
2023 · supplemented group · Overweight adults (28 females and 21 males across both study groups) with impaired fasting blood glucose; ages not reported
1.1 g60 days24
Efficacy and safety of HIMABERB® Berberine on glycemic control in patients with prediabetes: double-blind, placebo-controlled, and randomized pilot trial
2023 · Treatment Group · Adults aged 18–55, male or female, with prediabetes
1.5 g12 weeks17
Effect of Berberine Plus Bezafibrate Administration on the Lipid Profile of Patients with Mixed Dyslipidemia: A Pilot Clinical Trial
2021 · BBR · Adults aged 30–60 years with mixed dyslipidemia
1.5 g90 days12
Effect of Berberine Plus Bezafibrate Administration on the Lipid Profile of Patients with Mixed Dyslipidemia: A Pilot Clinical Trial
2021 · BBR plus bezafibrate · Adults aged 30–60 years with mixed dyslipidemia
1.5 g90 days12
Efficacy of a nutraceutical combination on lipid metabolism in patients with metabolic syndrome: a multicenter, double blind, randomized, placebo controlled trial
2019 · Armolipid Plus (AP) · Adults aged 18–70 with metabolic syndrome and left ventricular hypertrophy; men and women
500 mg24 weeks71
Pilot study on the efficacy and safety of berberine in people with metabolic syndrome and human immunodeficiency virus infection
2023 · berberine group · Adults living with HIV under virological suppression and with metabolic syndrome
1.5 g20 weeks22
Emulsification by vitamin E TPGS or Quillaja extract enhanced absorption of berberine without affecting its metabolism in humans
2022 · Vitamin E TPGS-emulsified berberine · Healthy men and women
800 mg1 day12
Effectiveness and safety of Bifidobacterium and berberine in human hyperglycemia and their regulatory effect on the gut microbiota: a multi-center, double-blind, randomized, parallel-controlled study
2021 · BB group (berberine and Bifidobacterium) · Adults aged 18–70 with newly diagnosed hyperglycemia
1 g16 weeks49
Effects of a nutraceutical combination (berberine, red yeast rice and policosanols) on lipid levels and endothelial function randomized, double-blind, placebo-controlled study
2010 · nutraceutical combination (NC) · Adults with hypercholesterolemia; mean age 55 years; 26 males and 24 females were randomized across both arms
500 mg10 weeks25
Effects of poly-bioactive compounds on lipid profile and body weight in a moderately hypercholesterolemic population with low cardiovascular disease risk: a multicenter randomized trial
2014 · Intervention (Armolipid Plus/AP) · Men and women older than 18 years with mild-moderate hypercholesterolemia and elevated LDL-c, candidates for lifestyle intervention without hypolipemic drug treatment
500 mg12 weeks51
Effects of a New Nutraceutical Formulation (Berberine, Red Yeast Rice and Chitosan) on Non-HDL Cholesterol Levels in Individuals with Dyslipidemia: Results from a Randomized, Double Blind, Placebo-Controlled Study
2017 · Nutraceutical compound · Men and women aged 18–75 with hypercholesterolemia and non-HDL-C ≥160 mg/dL
200 mg12 weeks30
Nutritional supplementation of hop rho iso-alpha acids, berberine, vitamin D₃, and vitamin K₁ produces a favorable bone biomarker profile supporting healthy bone metabolism in postmenopausal women with metabolic syndrome
2011 · intervention arm · Postmenopausal women with metabolic syndrome
200 mg14 weeks25
Effects of a New Combination of Medical Food on Endothelial Function and Lipid Profile in Dyslipidemic Subjects: A Pilot Randomized Trial
2019 · Nutraceutical B · Adults aged 18–75 with elevated serum cholesterol not requiring statins or statin-intolerant; people with cardiovascular disease and uncontrolled diabetes were excluded.
500 mg6 weeks23
Hop rho iso-alpha acids, berberine, vitamin D3 and vitamin K1 favorably impact biomarkers of bone turnover in postmenopausal women in a 14-week trial
2010 · treatment arm · Healthy postmenopausal women
200 mg14 weeks16